Genetic correction of PSA values using sequence variants associated with PSA levels by Gudmundsson, Julius et al.
Genetic correction of PSA values using sequence variants
associated with PSA levels
Julius Gudmundsson1,*, Soren Besenbacher1,*, Patrick Sulem1,*, Daniel F. Gudbjartsson1,
Isleifur Olafsson2, Sturla Arinbjarnarson3, Bjarni A. Agnarsson2,4, Kristrun R.
Benediktsdottir2,4, Helgi J. Isaksson2, Jelena P. Kostic1, Sigurjon A. Gudjonsson1, Simon
N. Stacey1, Arnaldur Gylfason1, Asgeir Sigurdsson1, Hilma Holm1, Unnur S. Bjornsdottir4,
Gudmundur I. Eyjolfsson5, Sebastian Navarrete6, Fernando Fuertes6, Maria D. Garcia-
Prats7, Eduardo Polo8, Ionel A. Checherita9, Mariana Jinga9, Paula Badea10, Katja K.
Aben11,12, Jack A. Schalken13, Inge M. van Oort13, Fred C. Sweep14, Brian T. Helfand15,
Michael Davis16, Jenny L. Donovan16, Freddie C. Hamdy17, Kristleifur Kristjansson1,
Jeffrey R. Gulcher1, Gisli Masson1, Augustine Kong1, William J. Catalona15, Jose I.
Mayordomo18, Gudmundur Geirsson2, Gudmundur V. Einarsson2, Rosa B. Barkardottir2,4,
Eirikur Jonsson2, Viorel Jinga9, Dana Mates10, Lambertus A. Kiemeney11,12,13, David E.
Neal19, Unnur Thorsteinsdottir1,4, Thorunn Rafnar1, and Kari Stefansson1,4
1deCODE genetics, IS-101 Reykjavik, Iceland. 2Landspitali-University Hospital, IS-101 Reykjavik,
Iceland. 3Glaesibaer, Clinical Research Laboratory, IS-108 Reykjavik, Iceland. 4Faculty of
Medicine, University of Iceland, IS-101 Reykjavik, Iceland. 5The Laboratory in Mjodd, Reykjavik,
Iceland. 6Division of Radiation Oncology, University Hospital, 50009, Zaragoza, Spain. 7Division
of Pathology, San Jorge General Hospital, 22004 Huesca, Spain 8Royo Villanova Hospital,
500014 Zaragoza, Spain. 9University of Medicine and Pharmacy Carol Davila, Bucharest,
Romania. 10National Institute of Public Health, Bucharest, Romania. 11Comprehensive Cancer
Center East, 6501 BG Nijmegen, The Netherlands. 12Department of Epidemiology, Biostatistics
and HTA, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands.
13Department of Urology, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The
Netherlands. 14Department of Laboratory Medicine, Radboud University Nijmegen Medical
Centre, 6500 HB Nijmegen, The Netherlands. 15Department of Urology, Northwestern University
Feinberg School of Medicine, Chicago, IL 60611, USA. 16School of Social and Community
Medicine, University of Bristol, Bristol BS8 1TH, UK. 17Nuffield Department of Surgical Science,
University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK 18Division of Medical
Oncology, University Hospital, 50009 Zaragoza, Spain. 19Oncology Centre, Addenbrooke’s
Hospital, University of Cambridge, Cambridge CB2 0QQ, UK.
Abstract
Correspondence and request for materials should be addressed to: K. S., (kstefans@decode.is) or J. G., (julius@decode.is). .
*These authors contributed equally to this work.
Author contribution: The study was designed and results were interpreted by J.G., S.B., P.S., D.F.G., A.K., U.T., T.R., and K.S.
Statistical analysis was carried out by S.B., P.S., D.F.G., J.G., and A.K. Subject recruitment, biological material collection and
handling along with genotyping was supervised and carried out by J.G., I.O., S.A., B.A., K.R.B., H.H., G.O., S.N.S., A.S., T.W., T.T.,
J.P.B., K.M.Mc., K.M.B., B.S., J.Godino, S.N., F.F., L.M., E.P., K.K.A., I.M.vO., B.K.S., B.T.H., D.K., C.Z., K.K., J.R.G., G.V.E.,
E.J., W.J.C., J.I.M., L.A.K., D.E.N. J.S., R.B.B., U.T. and T.R. Authors J.G., S.B., P.S., D.F.G., T.R. and K.S. drafted the manuscript.
All authors contributed to the final version of the paper. Principal investigators and corresponding authors for the respective
replication study populations are: The Netherlands, L.A.K.; Spain, J.I.M.; Chicago, W.J.C.; Romania, D.M.; the UK, F.C.H / D.E.N /
J.L.D.
Competing interests: The authors from deCODE are employees at deCODE Genetics Inc. K.S. is CEO and U.T. is VP of Research at
deCODE Genetics, Inc. DeCODE Genetics Inc. has a patent pending for the genetic correction of individual PSA levels.
NIH Public Access
Author Manuscript
Sci Transl Med. Author manuscript; available in PMC 2013 February 05.
Published in final edited form as:
Sci Transl Med. 2010 December 15; 2(62): 62ra92. doi:10.1126/scitranslmed.3001513.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Measuring serum levels of the prostate specific antigen (PSA) is the most common screening
method for prostate cancer. However, PSA levels are affected by a number of factors apart from
neoplasia. Notably, around 40% of the variability of PSA levels in the general population is
accounted for by inherited factors, suggesting that it may be possible to improve both sensitivity
and specificity by adjusting test results for genetic effects. In order to search for sequence variants
that associate with PSA levels, we performed a genome-wide association study and follow-up
analysis using PSA information from 15,757 Icelandic and 454 British men not diagnosed with
prostate cancer. Overall, we detected a genome-wide significant association between PSA levels
and SNPs at six loci: 5p15.33 (rs2736098), 10q11 (rs10993994), 10q26 (rs10788160), 12q24
(rs11067228), 17q12 (rs4430796), and 19q13.33 (rs17632542 (KLK3: I179T), each with Pcombined
< 3×10−10. Among 3,834 men who underwent a biopsy of the prostate, the 10q26, 12q24, and
19q13.33 alleles that associate with high PSA levels are associated with higher probability of a
negative biopsy (OR between 1.15 and 1.27). Assessment of association between the 6 loci and
prostate cancer risk in 5,325 cases and 41,417 controls from Iceland, the Netherlands, Spain,
Romania, and the US showed that the SNPs at 10q26 and 12q24 were exclusively associated with
PSA levels, whereas the other 4 loci also were associated with prostate cancer risk. We propose
that a personalized PSA cutoff value, based on genotype, should be used when deciding to
perform a prostate biopsy.
INTRODUCTION
In Western countries, prostate cancer is the most frequent cancer in men as well as one of
the leading causes of cancer related death in men. Early diagnosis and treatment are key
factors in determining the survival and prognosis of prostate cancer patients, prompting
intensive searches for biomarkers for screening. Currently, measuring serum levels of
prostate specific antigen (PSA) is the only accepted screening method for the disease. PSA
levels in the range of 2.5 ng/mL to 4 ng/mL are commonly used as a threshold when
deciding whether to perform a biopsy of the prostate. However, despite the widespread use
of the PSA screening test, it is limited both in specificity and sensitivity and substantial
controversy exists over its benefits for patients (1). This is mainly due to the fact that PSA is
not a specific marker of prostate cancer as its levels in serum increase in benign prostatic
hyperplasia and are affected by many other factors such as medications, urological
manipulations and inflammation. Notably, it has been shown that 33% of men with PSA
levels above 10 ng/ml had no evidence of prostate cancer at biopsy(2) and in a recent study
the fraction of men with PSA levels above 10 ng/ml and no evidence of prostate cancer at
biopsy was 47%(3). Furthermore, not all individuals with prostate cancer have raised levels
of PSA. By performing a biopsy on a set of individuals not selected for PSA levels,
Thompson and colleagues showed that 63% of prostate cancer patients (even prostate cancer
with Gleason score ≥ 7) have PSA levels lower than 3 ng/ml (4). Hence, current data suggest
that there is no PSA threshold below which prostate cancer can be excluded.
The utility of PSA in prostate cancer screening is currently being evaluated in two large
clinical trials, the prostate arm of the Prostate, Lung, Colon and Ovary Cancer Screening
Trial (PLCO) in the USA and the European Randomized Study of Screening for Prostate
Cancer (ERSPC). These trials are expected to establish whether screening has an effect on
prostate cancer mortality. The first results from these studies which were published last year
showed either no or a small reduction in prostate cancer-specific mortality in the PSA-
screened groups.(5, 6). Since then, it has been suggested that the initial reports from these
trials may have underestimated the beneficial effect of PSA screening as recent publications
report that PSA testing leads to a relative reduction of prostate cancer metastasis of 53% and
to a relative reduction of prostate cancer mortality close to 50%. However, over-diagnosis is
still reported to be substantial(7-9)
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One approach to increase the specificity and sensitivity of the PSA test is to work out a
model that defines the “normal” PSA value for a given man. Such a model would have to
take into account age, as the prevalence of both benign and malignant conditions that can
cause serum PSA elevation increases with age. Sequence variants are also important when
determining personal “normal” PSA levels, as it has been shown that expression of a large
percentage of genes is under genetic control of both cis and trans components (10).
Importantly, it has been shown that between 40% and 45% of the variability in PSA levels
among men in the general population can be accounted for by inherited factors (11, 12).
However, because these factors are largely unknown, it has not been possible to adjust for
them when interpreting the PSA results for a given individual. Recently, a variant
(rs2735839-G) was discovered near the KLK3 gene (which encodes PSA) that was shown to
predispose to prostate cancer (odds ratio OR= 1.2) (13). However, it was subsequently
shown that this variant associates with increased levels of PSA in men not diagnosed with
prostate cancer (14, 15). Hence, the reported risk of prostate cancer conferred by the variant
may be mediated principally through its effect on PSA levels. By correcting for this variant,
as well as additional sequence variants that affect PSA levels, both the sensitivity and the
specificity of the PSA screening test could be improved. This prompted us to perform a
genome-wide association study (GWAS) of sequence variants affecting population variation
in PSA levels. We then considered the effects of the PSA variants on subsequent prostate
cancer diagnoses.
RESULTS
Sequence variants associated with PSA levels
We performed a GWAS on serum PSA levels (adjusted for age and laboratory center) in
Icelandic men not diagnosed with prostate cancer according to data from the nationwide
Icelandic Cancer Registry (ICR). In total, we had access to PSA measurements from 4,620
individuals genotyped on Illumina chips, containing either the 317K or the 370K HumanHap
SNP panel. The analysis was augmented with data from 9,218 Icelanders with PSA
measurements whose genetic information could be partially inferred from genotyped
relatives (in-silico genotyping), using a previously described method (16). With respect to
statistical power, this augmentation is equivalent to an additional 2,918 individuals on
average (for details about the populations see Table S1). After quality control, 304,070
SNPs were available for the GWAS (for quantile-quantile plot of the results see Fig. S1).
Since the mean of the χ2 values was below 1 (χ2 = 0.91) we did not apply any genomic
control correction.
We selected all association signals with P < 1×10−5 for further analysis. This represented 12
SNPs at 6 different loci, of which four loci reached genome-wide significance after
accounting for the number of tests performed (P < 1.64×10−7 = 0.05/304,070) (Table S2a).
The genome-wide significant association signals were in or near genes at the following loci:
KLK3 on 19q13.33; HNF1B on 17q12; FGFR2 on 10q26.12; and TBX3 on 12q24.21. The
two suggestive association signals were at 10q11.23 near the MSMB gene and at 5p15.33
near the TERT gene (Table S2a).
To further investigate each of the six loci, we imputed genotypes based on data for 2.5
million SNPs from the Utah CEPH (Utah residents with ancestry from northern and western
Europe) (CEU) HapMap individuals for all SNPs present within a window of 500 Kb
centered on the most significant SNP. Based on this analysis, we identified three additional
SNPs; rs2736098-A at 5p15.33, rs4430796-A at 17q12 and rs17632542-T at 19q13.33, that
had a greater effect on PSA levels than any SNP present on the 317K chip (Table S2b).
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In an attempt to follow-up the observed associations with PSA levels in the Icelandic
discovery group, we genotyped the most significant SNP at each of the six loci in an
additional 1,919 Icelandic men with PSA level measurements and not diagnosed with
prostate cancer, and in 454 men from the ProtecT trial in the UK with PSA levels below 3
ng/ml and not diagnosed with prostate cancer. After combining significance levels from
Iceland and the UK, at least one SNP at each locus reached genome-wide significance
(Table 1).
For the strongest variant at each locus, the allele frequency was comparable in the Icelandic
and UK populations with frequencies ranging from 24% to 93% (Table 1) and their
observed effect on the PSA level ranges from 7% to 39% per allele in the Icelandic samples
and from 5% to 102% per allele in the UK samples (see Table 1 and Table S3 for genotype
effect of the variants). Variants in or near genes at three of these PSA loci, KLK3 on
19q13.33, HNF1B on 17q12, and MSMB 10q11, have previously been associated with
serum PSA levels in men not diagnosed with prostate cancer (13-15, 17-20).
The strongest overall association effect observed in the present study is with two SNPs,
rs2735839 and rs17632542, located near or in the PSA coding gene KLK3 (Table 1). Of
these, rs2735839-G (and highly correlated markers) has been reported previously to
associate with PSA levels (13-15, 21). The two SNPs are moderately correlated with each
other (D’=1 and r2=0.48 in UK; r2=0.56 in Iceland; r2=0.56 in HapMap CEU phase 3).
When we adjusted the results for each SNP, using the other SNP as a covariate and only
including individuals genotyped for both markers, results for rs17632542 remain significant
after adjusting for rs2735839 (Pcombined =5.51×10−8) whereas rs2735839 was marginally
significant after adjusting for rs17632542 (Pcombined =0.043). This suggests that the signal
from rs2735839 is subsumed by rs17632542. The SNP rs17632542 is a missense mutation
(an amino acid change denoted as I179T) in KLK3. This amino acid alteration is defined as
either neutral or deleterious by online protein structure algorithms (see Table S4). A
deleterious mutation could conceivably destabilize the protein, affecting circulating PSA
levels. Alternatively, the mutation may affect the antigenicity of the protein and thereby
influence its detectability in PSA tests. The alleles at the 10q11 (MSMB) and 17q12
(HNF1B) PSA loci are rs10993994-T and rs4430796-A or the same as those previously
reported to associate with PSA levels (17-19) as well as with prostate cancer risk (17, 22).
At the new PSA locus on 10q26, two variants, rs10788160-A and rs12413088-T, have
genome-wide significance and have similar effects on PSA levels. The two variants are
located within a region of linkage disequilibrium (LD) not known to contain any genes 324
and 305 Kb centromeric to the start of the FGFR2 gene, respectively. The two variants are
highly correlated (r2 = 0.85 in Iceland and r2 = 0.83 in the UK) and neither remains
significant after adjusting for the other. Given that the effects of the two variants cannot be
distinguished from each other, we elected to focus on rs10788160-A in subsequent
investigations. The PSA variant, rs10788160, is in very low linkage disequilibrium with the
variant rs1219648 (23) that confers risk of breast cancer (D’=0.15, r2=0.01 between
rs1219648 and rs10788160 in Iceland).
The most significant variant on 12q24, the second new PSA locus, is rs11067228-A. This
SNP is located in an LD-block that contains the gene TBX3, mutations in which have been
found to cause the ulnar-mammary syndrome (OMIM #181450) but have not previously
been shown to affect PSA levels.
At the third new PSA locus, on 5p15 near the TERT gene, two sequence variants, rs401681-
C and rs2736098-A, have comparable effects on PSA levels. They are moderately correlated
(D’=0.93 and r2 =0.39 between rs401681 and rs2736098 according to HapMap CEU Phase
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2), and because the effects of the variants cannot be distinguished from each other, we
elected to focus on rs2736098-A in subsequent analyses.
We estimated the fraction of the total variance in the levels of PSA explained by combining
the effect from the best marker at each of the six loci (rs2736098, rs10993994, rs10788160,
rs11067228, rs4430796 and rs17632542). The fraction accounted for is estimated to be 4.2%
in Iceland and 11.8% in the UK (see Table S5). In both populations, the missense mutation
in the KLK3 gene, rs17632542, accounts for half of the fraction of variance explained.
PSA variants and predisposition to prostate cancer
Variants at four of the six loci discussed above (KLK3, TERT, MSMB and HNF1B) have
previously been reported to be associated with risk of prostate cancer, although at different
degrees of significance (13, 17, 21, 22, 24) and some even with conflicting evidence (14).
Due to the potential confounding effects of PSA levels and prostate cancer, we examined
whether the PSA SNPs identified in this study also are associated with prostate cancer.
Based on a combined analysis of over 5,325 prostate cancer cases and 41,417 controls from
Iceland, the Netherlands, Spain, Romania and the US, we replicated the association of the
variants at the four loci with prostate cancer, each with a similar effect as described before
(odds ratios ranging from 1.10 to 1.21; see Table S6). Interestingly, in our data the missense
variant in KLK3, rs17632542, shows a stronger association with prostate cancer than the
strongest previously reported variant at this locus, rs2735839 (OR=1.39 and 1.19 for
rs17632542-T and rs2735839-G, respectively; see Table S6). In contrast, we found that the
variants at two of the three new PSA loci (FGFR2 and TBX3) do not associate significantly
with prostate cancer (Pcombined = 0.27 and 0.54; ORcombined = 0.97 and 1.01, for
rs10788160-A and rs11067228-A, respectively). The effects of these six variants on both
PSA levels and prostate cancer risk in Icelandic men is shown graphically in Fig. S2.
We next examined if any of the six loci associated with PSA levels have an effect on age at
diagnosis or aggressiveness of prostate cancer among patients in the 6 study groups from
Iceland, the Netherlands, Spain, Romania, the US and the UK. Only the missense mutation
in KLK3, rs17632542, is significantly associated with age at diagnosis; for each allele of
rs17632542-T that associates with higher PSA levels, the age at diagnosis was estimated to
decrease by nearly 9 months (0.71 year decrease, P = 0.016; see Table S7). When
performing a case-only analysis, we observed that for the missense mutation in KLK3,
rs17632542-T, the allele conferring risk of prostate cancer is significantly less frequent
(OR=0.78, P = 0.0099; see Table S8) among cases with more aggressive prostate cancer
(Gleason score > 6, and/or T3 (tumor extends through prostate capsule) or higher, and/or
node positive, and/or with metastatic disease) than among those cases with less aggressive
prostate cancer (Gleason score < 7, and T2 or lower). This is in agreement with findings
previously reported for the correlated variant at this locus, rs2735839 (25, 26). For none of
the five variants was there a significant effect on the aggressiveness of prostate cancer.
There has been controversy in the literature about the interpretation of the association of the
previously reported KLK3 variant (rs2735839) to prostate cancer , namely,whether the
observed association is due to a predisposition to the disease or mediated through the strong
effect of the KLK3 locus on PSA levels and therefore driven by the increasing frequency of
PSA testing (14, 15). To examine this, we stratified our Icelandic study group into cases
diagnosed before 1992, a time when the majority of patients were diagnosed without
undergoing PSA testing, and cases diagnosed from1992 to 2008, a period in which PSA
testing became more frequent. We used in-silico genotyping based on familial imputation to
augment the effective sample size of the group of cases, and we used 34,124 Icelanders not
known to have prostate cancer as controls. Our results for rs2735839-G show that the
association effect observed for the total case study group (OR = 1.15 (95% CI 1.04-1.27), P
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= 0.007) is confined to the group of cases diagnosed in 1992 or later (OR = 1.17 (95% CI.
1.06-1.29), P = 0.002), whereas cases diagnosed before 1992 have no increased risk (OR =
0.97 (95% CI. 0.83-1.13), P = 0.7; see Table S9). These results support the notion that the
prostate cancer risk reported for the KLK3 locus is driven by the increasing frequency of
PSA testing and subsequent biopsies over the last few decades. In contrast, the results for the
other five PSA loci are not substantially different for the two case subgroups (Table S9).
Effect of prostate cancer risk variants on PSA levels
We assessed the effect on PSA serum levels of the 47 sequence variants (23) conferring risk
of prostate cancer reported to date (see Table S10 and Fig. S2). Some loci have more than
one reported SNP. According to our results, there is a clear tendency for the allele associated
with prostate cancer risk also to be associated with high levels of PSA (see Table S10). This
is comparable to results previously reported by Wiklund et al. (15). For the vast majority of
the loci (N=41), their effect on PSA levels is weak (well below 0.1 standard units on the
scale of the distribution of the PSA measurements (see Methods in Supplementary Material)
and likely reflects undiagnosed prostate cancer cases in the PSA study group [also suggested
by Wiklund et al. (15)]. Exceptions are the variants at the KLK3 (rs2735839 and
rs17632542), HNF1B (rs4430769), MSMB (rs10993994) and TERT loci (rs2736098),
which are the loci of genome-wide significance in our PSA genome-wide association study.
Variants at two other loci 11q13 (rs11228565) and 8q24 (rs16901979) also have greater
effects on PSA levels but did not reach genome-wide significance (see Table S10). These six
loci can roughly be divided into two groups: those with a moderate effect on PSA levels
compared to their effect on prostate cancer risk (8q24, 11q13, 10q11 and 17q12) and those
comprising variants that have a relatively strong PSA effect compared to their effect on
prostate cancer risk (i.e. variants at KLK3 on 19q13.33, and TERT on 5p15; see Fig. S2).
Sequence variants and benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH), a common non-malignant overgrowth of prostate
tissue, can affect serum PSA levels. To determine if any of the PSA variants discussed
above are associated with BPH, we compared a set of 2,312 Icelandic men with
symptomatic BPH with 33,779 healthy Icelandic men. Men with symptomatic BPH were
defined as individuals either diagnosed after undergoing transurethral resection of the
prostate (TURP) or men over the age of 50 repeatedly using drugs in the G04C group of the
ATC classification (e.g. Tamsulosin, Finasteride and Dutasteride) for treating BPH between
the years 2003 and 2009. Except for rs2736098-T on 5p15 that showed a nominally
significant association (P = 0.048, OR=1.08; Table S11), no association was observed
between BPH and any of the remaining five PSA variants. Hence, BPH is unlikely to
account for a significant fraction of the observed association between PSA levels and the
variants discussed here.
PSA sequence variants and prostate biopsies
When screening for prostate cancer, a PSA level above a certain cutoff value is considered
an indicator that a needle biopsy is required. We wanted to assess if the variants that
associate with increased PSA levels also make men more prone to undergo a prostate tissue
biopsy. In our study group of 2,300 Icelandic men who underwent a prostate biopsy between
1998 and 2008, we observed a higher frequency of the allele increasing PSA levels in those
undergoing a biopsy compared with population controls for all six variants (1.04≤OR≤1.46;
all SNPs have P < 0.05 except rs11067228 on 12q24 which has P = 0.25, see Table S12).
Among the 2,300 individuals who had undergone a biopsy, cancer was diagnosed in ~50%
(a positive biopsy). When restricting the analysis to individuals with a biopsy but no
detectable prostate cancer (negative biopsy) and comparing them to population controls,
similar or even stronger results were observed (1.03 ≤ OR ≤ 1.82; all SNPs have P < 0.05
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except rs10993994 near MSMB which has P = 0.48, see Table S13). These results suggest
that unnecessary biopsies are more likely to be performed on individuals with elevated PSA
levels due to inherited factors.
From the UK study group, we had access to a group of approximately 1,400 men who had
undergone a biopsy. Of those, about one third were diagnosed with prostate cancer. Using
the Icelandic and the UK study groups of men who had been biopsied, we compared the
frequency of the PSA variants in positive and negative biopsies. Of the six loci, we found
that for the three PSA variants not primarily associated with prostate cancer risk (KLK3,
FGFR2 and TBX3), the alleles associated with increased PSA levels are significantly less
frequent among men with a positive biopsy than in men with a negative biopsy
(rs10788160-A near FGFR2 has ORcombined = 0.79 and Pcombined =5.4×10−6, rs11067228-
A near TBX3has ORcombined = 0.87 and Pcombined = 0.0034, rs17632542-T in KLK3 has
ORcombined = 0.77 and Pcombined = 0.013; see Table 2 and Table S14 for full details). The
results for these three variants demonstrate that the alleles associated with increased PSA
levels increase the probability that a normal prostate is biopsied.
Combined effect of PSA sequence variants
To summarize the overall effect on PSA levels, we combined the effect of the PSA variants
independently for the Icelandic and UK study populations, assuming a multiplicative model.
We chose to include in the analysis only the four sequence variants located near TERT,
FGFR2 TBX3 and KLK3 (rs2736098, rs10788160, rs11067228, and rs17632542,
respectively) that are primarily associated with PSA levels. The variants at the MSMB and
HNF1B loci were not included, as we consider them not to be primarily associated with PSA
levels. We realize that disentangling the effect of prostate cancer on PSA levels and the
impact of PSA levels on prostate cancer diagnosis is challenging. However, we based our
selection on the fact that out of the six PSA variants reported here, the variants at the MSMB
and HNF1B loci show the most significant association with prostate cancer (each SNP with
P< 4×10−13; Table S6).
Results from Iceland for the combined effect of the PSA variants show that for the top 5% of
the genetic PSA level distribution, the measured PSA levels are estimated to be 23% to 47%
higher than the population average. Similarly, for the bottom 5% of genetic PSA level
distribution, the measured PSA levels are estimated to be 30% to 56% lower than the
population average. In the UK study population, the estimated relative effect on PSA levels
is even greater; the range of increase is 40% to 92% for the top 5% of the distribution with
the greatest genotypic effect compared to the population average, whereas for the bottom
5% of the distribution, the range of the decrease is 53% to 80% compared with the
population average.
To demonstrate how the genetic effect of the four PSA sequence variants influences
individual PSA levels, we calculated a personalized PSA cutoff value corresponding to the
commonly used cutoff of 4 ng/ml. This was done by multiplying the value of 4 ng/ml with
the estimated relative genetic effect for the PSA SNPs. For individuals with the highest (top
5% of the distribution) genotypic effect, the personalized PSA cutoff value increased from 4
ng/ml to cutoff values between 4.9 and 5.9 ng/ml based on the estimates from Iceland, and
to cutoff values between 5.6 and 7.7 ng/ml based on the UK estimates. For the bottom 5% of
the relative genetic effect distribution, the personalized PSA cutoff values move from 4 ng/
ml to cutoff values between 1.7 and 2.8 ng/ml according to the Icelandic estimates, and to
cutoff values between 0.8 and 1.9 ng/ml according to the UK estimates (see Fig. 1). These
results demonstrate that for a substantial fraction of men undergoing PSA-based prostate
cancer screening, the personalized PSA cutoff value is shifted following correction for the
effect of the PSA sequence variants.
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We then assessed what fraction of 12,779 PSA measurements from 4,569 Icelandic men
would be reclassified, with respect to certain PSA cut-off values, after correcting them for
the four PSA sequence variants located near TERT, FGFR2 TBX3 and KLK3 (rs2736098,
rs10788160, rs11067228, and rs17632542, respectively). For a PSA cut-off value of 4ng/ml,
6.0% of the men had at least one PSA measurement reclassified; 3.0% moved from below to
above the cut-off value and 3.0% moved in the opposite direction. The results for a cut-off
value of 3ng/ml were similar, 6.9% of the men had at least one PSA measurement
reclassified; 3.1% moved from below to above the cut-off value and 3.8% moved in the
opposite direction (Table S15). If applied clinically, these men would be reclassified with
respect to whether or not they should undergo a biopsy.
Discriminatory power of biopsy outcome models
We calculated the area under the receiver-operating-characteristic curve (AUC) to assess the
discriminatory power of four models on the outcome of performing a biopsy of the prostate.
The four models included the following data: Model 1, PSA levels; model 2, the combined
prostate cancer risk estimates of 23 established sequence variants; model 3, genetic
correction of PSA values based on the sequence variants at the four PSA loci (5p15, 10q26,
12q24 and 19q33.3); model 4, PSA levels corrected for sequence variants and the combined
risk estimates of the 23 prostate cancer risk variants. In the analyses of the models, we used
415 Icelandic and 1,291 British men with information on biopsy outcome (i.e. biopsy
positive or biopsy negative) and PSA levels, as well as genotypes for the 23 established
prostate cancer variants and the PSA variants reported above. The model with genetic
correction of PSA levels (model 3) has an AUC of 70.9% and 58.5% for the Icelandic and
UK men, respectively (Fig. S3). When compared to model 1, which has an AUC of 70.4%
and 57.1% for the Icelandic and UK men, respectively, the inclusion of PSA levels corrected
for sequence variants (model 3) increases the discriminatory power by 0.5 and 1.4
percentage points in the Icelandic and UK groups, respectively. However, of the four models
assessed, model 4 has the greatest discriminatory power, with an AUC of 73.2% and 63.6%
for the Icelandic and UK men, respectively. Compared to model 1, the increased AUC of
model 4 is 2.8 and 6.5 percentage points for Icelandic and UK men, respectively. Hence, the
most gain in discriminatory power is achieved by including both the 23 prostate cancer risk
variants and the genetic correction of PSA levels. However, in order to better assess the
effect of the PSA and prostate cancer risk variants on PSA-based biopsies, this type of
modeling would have to be done in a population where biopsies are performed
systematically irrespective of individual PSA levels, similar to the approach taken in the
Prostate Cancer Prevention Trial (4).
DISCUSSION
In this study, we identified 6 loci that associate with PSA levels with genome-wide
significance. Variants at three of these loci had previously been shown to associate with
PSA levels, whereas three of the loci---at 10q26, 5p15 and 12q24---are new. Unlike the
variants previously reported to associate with PSA levels, two of the new loci, 12q24 and
10q26, do not associate with prostate cancer risk and the third locus, at 5p15, has only a
moderate effect on prostate cancer. Furthermore, we have shown that two of these variants
(rs10788160-A on 10q26 and rs11067228-A on 12q24), together with the KLK3 variant, are
associated with a greater probability of having a normal prostate biopsied. Hence, these new
markers primarily predict the outcome of PSA-based prostate cancer screening---that is, the
decision to perform a biopsy and the outcome of the biopsy--rather than predisposition to
prostate cancer.
In our study, we showed that a missense mutation, rs17632542-T, in the KLK3 gene on
19q33.33 is associated with higher PSA levels. This variant has a stronger effect on PSA
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levels than the variant rs2735839 previously reported at this locus. The KLK3 variant was
also found to predispose to prostate cancer but the effect was confined to the group of cases
diagnosed after the introduction of the PSA test. Furthermore, the association with prostate
cancer at the KLK3 locus was shown to be primarily with the less aggressive form of the
disease. For individuals undergoing a biopsy of the prostate, we have shown that the variant
rs17632542-T is associated with a greater probability of not being diagnosed with cancer.
Together, these results suggest that the reported association with prostate cancer at the
KLK3 locus is mainly driven by its effect on PSA levels and the increased frequency of PSA
testing in men.
Our results from estimating the combined relative effect of the 4 variants primarily
associated with PSA levels demonstrate a considerable variation in PSA levels between
individuals based on the genotypes of these 4 variants. By applying the combined genetic
effect on commonly used PSA cutoff values, a personalized PSA cutoff value can be
obtained. Furthermore, our results show after applying a genetic correction that 6-7% of
Icelandic men undergoing PSA-based prostate cancer screening have at least one PSA
measurement shifted above or below a commonly applied PSA cutoff value for deciding
whether to biopsy. Hence, these men would be reclassified with respect to whether they
should undergo a biopsy. The results of the AUC analysis show that when genetic correction
is applied to the PSA data from Icelandic and UK men an improvement in the prediction
accuracy is observed. The greatest improvement in prediction accuracy is seen when both
the genetic correction of PSA levels and the combined effect of prostate cancer risk variants
are included. For a screening test as important and widely used as the PSA test, having a
better way to interpret the measured serum PSA levels is likely to improve substantially the
clinical utility of the test.
We note that the estimates provided here are based solely on our Icelandic and UK study
populations and more accurate estimates could be obtained from large prospective studies.
Also, given the fast pace of discoveries in the current era of GWAS, additional variants
associated with PSA levels could be discovered, suggesting the need for updating of such
multivariate models.
In combination with information about age, ethnicity, and family history of the disease,
estimates of the effect of genetic variation on prostate cancer risk and PSA levels could lay a
foundation for the development of individual prostate cancer screening strategies that would
have the ultimate goal of reducing cost and improving quality of life.
Material and Methods
Results from PSA testing were collected from the three clinical laboratories performing the
great majority of all PSA measurements in Iceland. The series of data spanned a period of 15
years (from1994 to 2009). In total we had information about PSA values from 15,757 men
(for further details see Table S1). The men have not been diagnosed with prostate cancer
according to the nation-wide Icelandic Cancer Registry (ICR), and had not undergone TURP
between 1983 and 2008, based on a list from the Landspitali-University Hospital where 90%
of all TURP procedures in the country are performed.
Recruitment of men aged 50-69 in the ‘Prostate Testing for Cancer and Treatment’ trial
(ProtecT) took place at nine sites in the UK. From the ProtecT trial study group, the
following number of samples were selected for the present study: 524 men with PSA values
>3 ng/ml and diagnosed with prostate cancer after undergoing a needle biopsy, 960 men
with PSA values between 3 ng/ml and 10 ng/ml but not diagnosed with prostate cancer after
undergoing a 10-core needle biopsy, and 454 men with PSA values < 3 ng/ml who had not
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undergone prostate biopsies. For a detailed description of study subjects, genotyping and
statistical methods see Supplementary Material.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Cumulative distribution of the personalized PSA cutoff values after genetic correction
Shown is the cumulative distribution (the x-axis represents the percentile of the population)
of the personalized PSA cutoff values after applying a genetic correction to the commonly
used PSA cutoff value of 4 ng/ml (shown on the y-axis), using the relative genetic estimates
for the 4 PSA SNPs (rs2736098, rs10788160, rs11067228, and rs17632542), in the Icelandic
(red line) and UK (blue line) study populations.
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